Indonesia: COVID-19 vaccines market revenue 2028| ��ƽ��

Revenue of the COVID-19 vaccines market in Indonesia from 2021 to 2022 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

More information

Supplementary notes

Data provided by ��ƽ�� Market ��ƽ�� are estimates.

This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

A detailed methodology can be found in the ��ƽ�� Market Outlook.

Citation formats

In 2022, the coronavirus (COVID-19) vaccine market in Indonesia generated an annual revenue of around *** million U.S. dollars, indicating a sharp decline compared to the previous year. The ��ƽ�� Health Market Outlook estimated the revenue of the market would continue to decrease and reach around *** million U.S. dollars by 2028.